<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633776</url>
  </required_header>
  <id_info>
    <org_study_id>Perforomist CT Study</org_study_id>
    <nct_id>NCT00633776</nct_id>
  </id_info>
  <brief_title>Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)</brief_title>
  <official_title>Perforomist Versus Foradil Evaluated by Inspiratory Capacity and HRCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dey, L.P.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of nebulized formoterol fumarate&#xD;
      (Perforomist) to dry-powder inhaler formoterol fumarate (Foradil). Perforomist is a solution&#xD;
      that is made into very fine spray (using a nebulizer) that is then breathed in over 10-15&#xD;
      minutes. Foradil is taken in a single quick, deep inhalation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation requires 3 visits over 1-5 weeks. The first visit (Screening) will help&#xD;
      determine subjects' eligibility through medical history, physical exam, lung function&#xD;
      testing, and exercise testing. Those who qualify will be invited back to 2 test visits, at&#xD;
      which subjects will undergo lung function testing and high-resolution CT scans before and&#xD;
      after treatment with one of the study drugs. All subjects will take both study drugs: those&#xD;
      who are randomized to Perforomist at Test Visit 1 will take Foradil at Test Visit 2, and vice&#xD;
      versa.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor withdrew funding prior to study initiation&#xD;
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">January 2009</completion_date>
  <primary_completion_date type="Anticipated">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distal airway measurements in COPD using inspiratory capacity as measure of small airways patency</measure>
    <time_frame>End of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in anatomic lobar air-trapping by HRCT due to small airways dilation between Perforomist and Foradil</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>COPD</condition>
  <condition>Chronic Bronchitis</condition>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 1; Formoterol 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol fumarate 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 1; Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>formoterol fumarate</intervention_name>
    <description>Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Perforomist (nebulized formoterol fumarate)</other_name>
    <other_name>Foradil (aerosolizer dry powder formoterol fumarate)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic subjects with moderate to severe COPD&#xD;
&#xD;
          -  Age greater than/equal to 40 years&#xD;
&#xD;
          -  History of smoking greater than/equal to 20 pack-years of cigarettes&#xD;
&#xD;
          -  No history of asthma (in the opinion of the investigator)&#xD;
&#xD;
          -  No COPD exacerbations within the past 2 months requiring oral corticosteroids or&#xD;
             hospitalization.&#xD;
&#xD;
          -  No continuous oxygen therapy&#xD;
&#xD;
          -  Subjects with a body mass index less than 15 or greater than 38&#xD;
&#xD;
          -  Patients must be without other clinically significant illnesses or condition that&#xD;
             might interfere with the study, including but not limited to uncontrolled&#xD;
             hypertension, cardiovascular disease, cardiac arrhythmia, diabetes, hyperthyroidism,&#xD;
             seizure disorder or any history of pheochromocytoma&#xD;
&#xD;
          -  Be using medically acceptable birth-control measures if a female of child-bearing&#xD;
             potential&#xD;
&#xD;
          -  Not be pregnant or breastfeeding&#xD;
&#xD;
          -  Be willing to withhold any existing short or long-acting bronchodilators for the&#xD;
             appropriate time period prior to each test day (see below). Use of inhaled&#xD;
             corticosteroids is not exclusionary, but will be maintained at a constant level&#xD;
             throughout the study.&#xD;
&#xD;
          -  Must be willing and able to perform spirometry, slow vital capacity, plethysmography,&#xD;
             DLCO, and 6 minute walk after appropriate instruction.&#xD;
&#xD;
          -  No known allergy or contradiction to albuterol or formoterol or prior significant&#xD;
             adverse reactions to other beta agonists.&#xD;
&#xD;
          -  No hypersensitivity to milk protein. Bloating or gas from lactose is not an exclusion.&#xD;
&#xD;
          -  No use of beta-blockers (selective or non-selective), phenothiazines (thioridazine),&#xD;
             or other drugs that may interact with formoterol or albuterol for the duration of the&#xD;
             study. Washout of greater than seven half-lives of the drug prior to the study.&#xD;
&#xD;
          -  No use of cardiac anti-arrhythmics Class Ia (e.g., disopyramide, procainamide,&#xD;
             quinidine), or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol),&#xD;
             terfenadine, astemizole, mizolastine and any other drug with potential to&#xD;
             significantly prolong the QT interval.&#xD;
&#xD;
          -  No use of non-potassium sparing diuretics unless in fixed combination with potassium&#xD;
             sparing diuretic.&#xD;
&#xD;
          -  No investigational drugs within 30 days&#xD;
&#xD;
          -  No subjects affiliated with the Division of Pulmonary, Critical Care Medicine and&#xD;
             Hospitalists, David Geffen School of Medicine&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Post-albuterol FEV1/FVC less than lower limit of normal (Hankinson)&#xD;
&#xD;
          -  Post-albuterol FEV1 between 30% and 60% predicted (Hankinson)&#xD;
&#xD;
          -  An increase in FEV1 after albuterol sulfate HFA of at least 5% and 50 ml&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald P Tashkin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA David Geffen School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Kleerup, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>UCLA David Geffen School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>March 4, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <name_title>Donald Tashkin, M.D.</name_title>
    <organization>University of California, Los Angeles (UCLA) David Geffen School of Medicine</organization>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Chronic bronchitis</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Perforomist</keyword>
  <keyword>Foradil</keyword>
  <keyword>CT</keyword>
  <keyword>lung function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

